ETFs OneSource Specialty Pharma Limited

ONESOURCE

INE013P01021

Biotechnology & Medical Research

Market Closed - NSE India S.E. 14:05:09 29/10/2026 +03			5-day change	1st Jan Change
1,569.60 ^INR	-0.51%		+15.66%	-13.31%

10-27	OneSource Specialty Pharma Limited, Q2 2027 Earnings Call, Oct 27, 2026
10-27	OneSource Specialty Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI

ETFs positioned on OneSource Specialty Pharma Limited

Name	YTD change	Weight	AuM
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+4.97%	-	37 M€
CI GROWTH ASSET ALLOCATION ETF -CAD	+9.73%	-	67 M€
ISHARES MSCI INDIA SMALL-CAP ETF - USD	-.--%	0.27%	773 M€
ISHARES MSCI EM SMALL CAP UCITS ETF - USD	+3.55%	0.06%	337 M€
STATE STREET SPDR S&P EMERGING MARKETS SMALL CAP ETF - USD	+2.06%	0.05%	701 M€
ISHARES MSCI EMERGING MARKETS SMALL-CAP ETF - USD	+4.51%	0.04%	380 M€
XTRACKERS NIFTY 500 INDIA ETF - USD	-13.96%	0.04%	5 M€
STATE STREET SPDR S&P EMERGING ASIA PACIFIC ETF - USD	+7.38%	0.03%	441 M€
AVANTIS RESPONSIBLE EMERGING MARKETS EQUITY ETF - USD	+13.67%	0.02%	216 M€
AVANTIS EMERGING MARKETS EQUITY ETF - USD	+14.33%	0.02%	26,721 M€
VANGUARD ESG EMERGING MARKETS ALL CAP UCITS ETF DIST - USD	+12.48%	0.02%	24 M€
AVANTIS EMERGING MARKETS VALUE ETF - USD	+4.96%	0.02%	1,490 M€
VANGUARD ESG EMERGING MARKETS ALL CAP UCITS ETF ACC - USD	+14.40%	0.01%	117 M€
VANGUARD FTSE EMERGING MARKETS ALL CAP INDEX ETF - CAD	+6.82%	0.01%	3,276 M€
VANGUARD FTSE EMERGING MARKETS ETF - USD	+4.96%	0.01%	126,032 M€
ISHARES CORE MSCI EMERGING MARKETS IMI ETF - JPY	+12.12%	0.01%	189 M€
ISHARES MSCI EM IMI SCREENED UCITS ETF - ACCUMULATING - USD	+20.14%	0.01%	6,575 M€
ISHARES CORE MSCI EMERGING MARKETS IMI INDEX ETF - CAD	+15.29%	0.01%	3,282 M€
ISHARES CORE MSCI EMERGING MARKETS IMI INDEX ETF - USD	+13.85%	0.01%	14 M€
ISHARES CORE MSCI EMERGING MARKETS ETF - USD	+13.09%	0.01%	158,599 M€
ISHARES MSCI EM IMI SCREENED UCITS ETF - DISTRIBUTING - USD	+13.87%	0.01%	1,403 M€
DEFINED DURATION 20 ETF - USD	+11.37%	0%	19 M€
ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF - USD	+10.48%	0%	60,535 M€
VANGUARD ESG GLOBAL ALL CAP UCITS ETF - ACCUMULATING - USD	+18.00%	0%	1,190 M€
VANGUARD ESG GLOBAL ALL CAP UCITS ETF - DISTRIBUTING - USD	+16.81%	0%	699 M€
VANGUARD TOTAL INTERNATIONAL STOCK ETF - USD	+10.59%	0%	163,510 M€
CAMBRIA GLOBAL MOMENTUM ETF - USD	+14.08%	0%	73 M€
ELM MARKET NAVIGATOR ETF - USD	+7.41%	0%	594 M€
STATE STREET SPDR GLOBAL ALLOCATION ETF - DISTRIBUTING - USD	+6.35%	0%	317 M€
NED DAVIS RESEARCH 360 DYNAMIC ALLOCATION ETF - USD	+9.99%	0%	235 M€
ISHARES CORE MSCI ALL COUNTRY WORLD EX CANADA INDEX ETF - CAD	+13.78%	0%	3,286 M€
VANGUARD FTSE GLOBAL ALL CAP EX CANADA INDEX ETF - CAD	+13.47%	0%	2,612 M€
MYRIAD DYNAMIC ASSET ALLOCATION ETF - USD	+15.28%	0%	473 M€
OVERLAY SHARES FOREIGN EQUITY ETF - USD	+2.90%	0%	56 M€
VANGUARD TOTAL WORLD STOCK ETF - USD	+11.70%	0%	81,610 M€
RETURN STACKED GLOBAL STOCKS & BONDS ETF - USD	+7.55%	0%	526 M€
THE BRINSMERE FUND GROWTH ETF - USD	+8.46%	0%	391 M€
ISHARES LIFEPATH TARGET DATE 2070 ETF - USD	+12.62%	0%	16 M€
ISHARES CORE MSCI ALL COUNTRY WORLD EX CANADA INDEX ETF - USD	0.00%	0%	25 M€
RPAR RISK PARITY ETF - USD	+1.03%	0%	580 M€
UPAR ULTRA RISK PARITY ETF - USD	-0.78%	0%	59 M€
ISHARES LIFEPATH TARGET DATE 2055 ETF - USD	+12.62%	0%	60 M€

1 2

OneSource Specialty Pharma Limited is an India-based Contract Development and Manufacturing Organization (CDMO). The Company offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply. The Company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. Its integrated services offer comprehensive biologics solutions. The Company develops a variety of soft gelatin capsules including traditional and enteric softgels, vegan capsule alternatives, chewable formats and specialty dosage forms, and liposomal systems and applicaps. It also provides end-to-end development and manufacturing of sterile injectable products.

Employees

1,674

Sector

Biotechnology & Medical Research

More about the company